Previous 10 | Next 10 |
EMERYVILLE, Calif., Dec. 21, 2020 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA) (“XOMA” or the “Company”) today announced the closing of its previously announced underwritten registered public offering of 984,000 shares, which includes the underwriters opti...
XOMA ([[XOMA]] -1.8%) announced the pricing of its underwritten registered public offering of 880k shares of 8.625% Series A Cumulative Perpetual Preferred Stock, with liquidation preference of $25/share at an initial public offering price of $25/share, expected gross proceeds of $22M.Underwr...
EMERYVILLE, Calif., Dec. 10, 2020 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA) (“XOMA” or the “Company”) today announced the pricing of its underwritten registered public offering of 880,000 shares of 8.625% Series A Cumulative Perpetual Preferred Stock, w...
EMERYVILLE, Calif., Dec. 10, 2020 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA) (“XOMA” or the “Company”) today announced it has commenced an underwritten registered public offering of shares of its Series A Cumulative Perpetual Preferred Stock, with liquid...
XOMA (XOMA) earned a $2M milestone payment from Takeda Pharmaceutical as the first patient has been dosed in its Phase 2 study to evaluate safety, tolerability, and efficacy of mezagitamab (TAK-079) in participants with generalized myasthenia gravis.XOMA and Takeda entered into a collaboratio...
EMERYVILLE, Calif., Nov. 16, 2020 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA) (“XOMA” or the “Company”) today announced it has earned a $2 million milestone payment from Takeda Pharmaceutical Company Limited as the first patient has been dosed in its Phas...
XOMA (XOMA) earned a $1M milestone payment from Agenus (AGEN) related to Merck's advancement of MK-4830 into a Phase 2 study in patients with advanced non-small cell lung cancer previously treated with anti-programmed cell death receptor ligand 1 therapy.MK-4830 is part of the company's first...
EMERYVILLE, Calif., Nov. 11, 2020 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA) (“XOMA” or the “Company”) today announced it has earned a $1 million milestone payment from Agenus Inc. (NASDAQ: AGEN) related to Merck’s advancement of MK-4830 into a Ph...
XOMA (XOMA): Q3 GAAP EPS of -$0.10 beats by $0.03.Revenue of $0.6M (-93.0% Y/Y) misses by $2.29M.Cash balance of $45.7M.Press Release For further details see: XOMA EPS beats by $0.03, misses on revenue
Company recently earned a $ 25 million milestone payment as NIS793 advanced to Phase 2 development in advanced pancreatic cancer An u ndisclosed partner entered Phase 2 development, triggering a $0.5 million milestone Rezolute’s financing res...
News, Short Squeeze, Breakout and More Instantly...
2024-07-05 16:40:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
EMERYVILLE, Calif., June 12, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today it has received an $8.1 million milestone payment from Viracta Therapeutics, Inc., related to Day One Biopharmaceuticals’ recent sale of its Priority Revie...
2024-06-04 04:04:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...